FOUR-STRAIN COVERAGE

Four-strain coverage with a live vaccine—engineered to help prevent the flu, not cause it1,2

The live attenuated influenza virus strains in FLUMIST QUADRIVALENT are

Attenuated

The disease-causing properties of the virus strains are modified to not cause influenza1

Virus strain replicating efficiently in cooler areas image Virus strain do not replicate in lungs image

Cold adapted

The virus strains replicate efficiently in the nasopharynx at 25°C, a temperature that is restrictive for replication of many wild-type influenza viruses1

Temperature sensitive

The virus strains do not replicate at 37°C to 39°C, temperatures at which many wild-type influenza viruses grow efficiently1

FLUMIST QUADRIVALENT is a live attenuated vaccine like the vaccines for measles, mumps, rubella, varicella, and rotavirus1

FLUMIST QUADRIVALENT helps protect against multiple strains1:
A Strain (H1N1)
A Strain (H3N2)
Two B Strains

IMPORTANT SAFETY INFORMATION

  • FLUMIST QUADRIVALENT is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy
  • In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist
  • Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FLUMIST QUADRIVALENT administration. FLUMIST QUADRIVALENT has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • FLUMIST QUADRIVALENT has not been studied in immunocompromised persons
  • The safety of FLUMIST QUADRIVALENT in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine
  • FLUMIST QUADRIVALENT may not protect all individuals receiving the vaccine
  • The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported were runny nose or nasal congestion in persons 2-49 years, fever >100°F in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FLUMIST QUADRIVALENT, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18-49 years who received FLUMIST QUADRIVALENT, 44% reported runny nose or nasal congestion and 19% reported sore throat

FLUMIST QUADRIVALENT is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUMIST QUADRIVALENT is for intranasal administration only.

Please see full Prescribing Information for FLUMIST QUADRIVALENT, including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.